CYCLERION THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.5 USD | +8.76% |
|
+5.42% | +4.48% |
| Mar. 05 | Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Cyclerion Therapeutics, Inc. Appoints Regina Graul as President | CI |
Financials (USD)
| Sales 2022 | 1.62 | Sales 2023 | - | Capitalization | 8.19M |
|---|---|---|---|---|---|
| Net income 2022 | -44M | Net income 2023 | -5M | EV / Sales 2022 | 17,563,610 x |
| Net cash position 2022 | 13.38 | Net cash position 2023 | 7.57 | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.65
x | P/E ratio 2023 |
-1.49
x | Employees | 1 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 74.53% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +8.76% | ||
| 1 week | +5.42% | ||
| Current month | +9.38% | ||
| 1 month | +6.06% | ||
| 3 months | +1.01% | ||
| 6 months | +6.71% | ||
| Current year | +4.48% |
1 week
3.15
3.50
1 month
2.803.98
Current year
2.544.30
1 year
1.756.75
3 years
1.7597.20
5 years
1.75349.20
10 years
1.75457.00
| Managers | Title | Age | Since |
|---|---|---|---|
Regina Graul
PSD | President | - | Dec. 03 |
Peter Hecht
BRD | Director/Board Member | 60 | 19-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Errol de Souza
CHM | Chairman | 70 | 21-04-25 |
Terry McGuire
BRD | Director/Board Member | 68 | 19-03-31 |
Peter Hecht
BRD | Director/Board Member | 60 | 19-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 3.218 | +1.20% | 443 |
| 24-04-16 | 3.18 | -4.22% | 527 |
| 24-04-15 | 3.32 | -1.48% | 2,358 |
| 24-04-12 | 3.37 | +10.51% | 14,231 |
| 24-04-11 | 3.05 | -1.63% | 4,140 |
Delayed Quote Nasdaq, April 19, 2024 at 04:30 pm EDT
More quotes
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Companyâs portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.
Calendar
2024-04-30
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +4.48% | 8.17M | |
| -1.42% | 41.35B | |
| +42.15% | 40.38B | |
| +1.97% | 39.05B | |
| -14.19% | 26.67B | |
| +1.82% | 24.07B | |
| -24.55% | 18.36B | |
| -4.07% | 11.68B | |
| +21.36% | 11.6B | |
| +8.20% | 11.15B |
- Stock Market
- Equities
- CYCN Stock
